PARP inhibitors - current status and the walk towards early breast cancer

Breast

Volumn 20, Issue SUPPL. 3, 2011, Pages

  Glendenning, Jennifer ^a   Tutt, Andrew ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Adjuvant; PARP inhibitor; Targeted therapy; Triple negative breast cancer

Indexed keywords

AGO 14699; BRCA1 PROTEIN; BRCA2 PROTEIN; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CEP 9722; CISPLATIN; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; E 7016; GEMCITABINE; GP 12016; INIPARIB; INO 1001; KU 0058684; KU 0058948; MK 4827; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; OXALIPLATIN; PACLITAXEL; PF 01367338; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VELIPARIB;

ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST CARCINOGENESIS; BREAST SURGERY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL CLONE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL (TOPIC); CONSTIPATION; DNA DAMAGE; DNA REPAIR; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG SENSITIZATION; DRUG TOLERABILITY; EARLY CANCER; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; FATIGUE; GENE MUTATION; GENE SILENCING; HOMOLOGOUS RECOMBINATION; HUMAN; IONIZING RADIATION; LONG TERM CARE; LOSS OF FUNCTION MUTATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; SOMATIC CELL; SOMATIC MUTATION; STUDY DESIGN; THROMBOCYTOPENIA; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

EID: 80054869232     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/S0960-9776(11)70288-0     Document Type: Review

References (67)

1. Hanahan D, Weinberg RA Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
2. Harper JW, Elledge SJ The DNA damage response: 10 years after. Mol Cell 2007, 28(5):739-745.
3. Kaelin WG The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005, 5(9):689-698.
4. Schreiber V, Dantzer Fo, Ame J-C, de Murcia g Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006, 7(7):517-528.
5. Ossovskaya V, Koo IC, Kaldjian EP, Alvares C, Sherman BM Upregulation of poly(ADP-ribose) polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types. Genes Cancer 2010, 1(8):812-821.
6. Goncalves A, Finetti P, Sabatier R, et al. Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Res Treat 2010, 10.1007/sl0549-010-1199-y.
7. Farmer H, McCabe N, Lord C, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
8. Bryant H, Schultz N, Thomas H, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
9. Donawho CK, Luo Y ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumour models. Clin Cancer Res 2007, 13(9):2728-2737.
10. Ossovskaya V, Li L, Broude E, et al. BSI-201 enhances the activity of multiple classes of cytotoxic agents and irradiation in triple negative breast cancer. AACR Meeting Abstracts 2009, 2009(2). Abstract #5552.
11. Thomas HD, Calabrese CR, Batey MA, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther 2007, 6(3):945-956.
12. Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sri 2008, 105(44):17079-17084.
13. Takahashi M, Koi M, Balaguer F, Boland CR, Goel A MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin and a poly(ADP-ribose) polymerase inhibitor. J Biol Chem 2011, 10.1074/jbc.M110.198804.
14. Menear KA, Adcock C, Boulter R, et al. 4-[3-(4-Cyclopropanecarbonylpiperazine-l-carbonyl)-4-fluorobenzyl]-2H-phthalazin-l-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1]. Med Chem 2008, 51(20):6581-6591.
15. Fong PC, Boss DS, A YT, et al. Inhibition of poly(ADP-ribose) polymerase in tumours from BRCA mutation carrier. N EnglJ Med 2009, 361(2):123-134.
16. Tutt AN, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inihibitor in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376(9737):235-244.
17. Gelman KA, Hirte HW, Robidoux A, et al. Can we define tumours that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. J Clin Oncol 2010, 28(15s). abstract 3002.
18. Dent RA, Lindeman GJ, demons M, et al. Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/I I multicenter trial. J Clin Oncol 2010, 28(15s). abstract 1018.
19. Palma JP, Rodrugyez LE, Bontcheva-diaz VD, et al. The PARP Inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer Res 2008, 28(5A):2625-2635.
20. Isakoff SJ, Overmoyer B, Tung NM, et al. A phase II trial of the PARP inhibitor veliparib (ABT-888) and temozolamide for metastatic breast cancer. J Clin Oncol 2010, 28(15s). abstract 1019.
21. Ossovskaya V, Li L, Bradley C, Sherman B Activity of BSI-201, a potent poly(ADP-ribose) polymerase (PARP1) inhibitor, alone and in combination with topotecan in human ovarian xenografts. AACR Meeting Abstracts 2008, 2008(1). Abstract #2311.
22. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N EnglJ Med 2011, 354(3):205-214.
23. Tentori L, Leonetti C, Scarsella M, et al. Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. IntJ Oncol 2005, 26(2):415-422.
24. Miknyoczki SJ, Jones-Bolin S, Pritchard S, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003, 2(4):371-382.
25. Sandhu SK, Wenham RM, Wilding G, et al. First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumour activity in BRCA deficient and sporadic ovarian cancers. J Clin Oncol 2010, 28(15s). abstract 3001.
26. Tutt A, Bertwistle D, Valentine J, et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBOJ 2001, 20(17):4704-4716.
27. Zhang J, Powell SN The role of the BRCA1 tumour suppressor in DNA double-strand break repair. Mol Cancer Res 2005, 3(l):531-539.
28. Moynahan ME, Pierce AJ, Jasin M BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001, 7(2):263-272.
29. Gluz O, Liedtke G, Gottschalk N, Pusztai L, Nitz U, Harbeck N Triple-negative breast cancer - current status and future directions. Ann Oncol 2009, 20(12):1913-1927.
30. Liedtke C, Mazouni c, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008, 26(8):1275-1281.
31. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl Cancer Inst 2003, 95(19):1482-1485.
32. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003, 100(14):8418-8423.
33. Nielsen TO, Forrest DH, Karaca G, et al. Immunohistochemical and clinical characterisation of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
34. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13(8):2229-2234.
35. Cheang MCU, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than the triple-negative phenotype. Clin Cancer Res 2008, 14(15):1368-1376.
36. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11(16):5678-5685.
37. Mahany JJ, Lewis N, Heath El, et al. A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors. J Clin Oncol 2008, 26(15s). abstract 3579.
38. Moulder S, Mita MM, Bradley C, Rocha C, Harris L A Phase lb study to assess the safety and tolerability of the PARP inhibitor iniparib (BSI-201) in combination with irinotecan for the treatment of patients with metastatic breast cancer (MBC). SABCS 2010, Abstract P6-15-01.
39. Turner NC, Tutt AN, Ashworth A Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004, 4:814-819.
40. Sakai W, Swisher EM, Jacquemont C, et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 2009, 69(16):6381-6386.
41. Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008, 451(7182):1111-1115.
42. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010, 10:293-301.
43. Ferraris DV Evolution of poly(ADP-ribsose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J Med. Chem 2010, 53(12):4561-4584.
44. Kopetz S, Mita MM, Mok I, et al. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. J Clin Oncol 2008, 26(15s). abstract 3577.
45. Hennessy BTJ, Timms KM, Carey MS, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly(ADP ribose) polymerase inhibitors in ovarian cancer.;. Clin Oncol 2010, 28(22):3570-3576.
46. Press J, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008, 8(1):17.
47. Hammond EM, Hayes DF, Allred DC, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast CancerJ. Clin Oncol 2010, 28(16):2784-2795.
48. Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98 J. Clin Oncol 2007, 25(25):3846-3852.
49. Rakha E, Reis-Filho JS Basal-like breast cancer: from expression profiling to routine practice. Arch Pathol Lab Med 2009, 133(6):860-868.
50. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast cancer. Breast Cancer Res 2007, 9(5):R65.
51. Grushko TA, Nwachukwa C, Charoenthammaraksa S, et al. Evaluation of BRCA1 inactivation by promotor methylation as a marker of triple-negative and basal breast cancer. J Clin Oncol 2010, 28(15s). abstract 10510.
52. Parker JS, Mullins M, Cheang MCU, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27(8):1160-1167.
53. Beger C, Pierce LN, Kruger M, et al. Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc NatlAcadSci USA 2001, 98(1):130-135.
54. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007, 26:2126-2132.
55. Vollebergh MA, Lips EH, Nederlof PM, et al. An aCGH classifier derived from BRCAl-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol 2010: doi 10.1093/annonc/mdq624.
56. Stephens PJ, McBride DJ, Lin M-L, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009, 462(7276):1005-1010.
57. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J C/in. Oncol 2010, 28(7):1145-1153.
58. Juul N, Kim J, Eklund AC, et al. A genomic-profile derived summary measure of chromosomal rearrangements predicts response to treatment with the DNA-damaging agent cisplatin. SABCS 2009.
59. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006, 66(16):8109-8115.
60. Chan N, Pires IM, Coakley C, et al. Contextual synthetic lethality of cancer cell kill based on the tumour microenvironment. Cancer Res 2010, 70(20):8045-8054.
61. Graeser M, McCarthy A, Lord CJ, et al. A marker of homologous recombination predicts pathological complete response to neoadjuvant chemotherapy in primary breast cancer, din. Cancer Res 2010, 16(24):6159-6168.
62. Inbar-Rozensal D, Castiel A, Visochek L, et al. A selective eradication of human nonhereditary breast cancer cell by phenanthridine-derived polyADP-ribose polymerase inhibitors. Breast Cancer Research 2009, 11(6):111.
63. Alii E, Sharma VB, Sunderesakumar P, Ford JM Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 2009, 69(8):3589-3596.
64. Devalaraja-Narashimha K, Padanilam BJ PARP-1 inhibits glycolysis in ischemic kidneysj. Am SocNephrol 2008, 20(1):95-103.
65. Chan JK, Ueda SM, Sugiyama VE, et al. Analysis of Phase II studies on targeted agents and subsequent Phase III trials: what are the predictors for success?;. Clin Oncol 2008, 26(9):1511-1518.
66. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007, 25(28):4414-4422.
67. von Minckwitz G, Untch M, Nuesch E, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2011, 125(1):145-156.